PDF icon PDF herunterladen
Thromb Haemost 1989; 61(01): 093-096
DOI: 10.1055/s-0038-1646533
Original Article
Schattauer GmbH Stuttgart

Absence of Potentiation with Murine Antiplatelet GPIIb/IIIa Antibody of Thrombolysis with Recombinant Tissue-Type Plasminogen Activator (rt-PA) in a Canine Venous Thrombosis Model

D Spriggs
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
H K Gold
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
Y Hashimoto
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
E Van Houtte
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
J Vermylen
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
D Collen
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 14. Juni 1988

Accepted after revision 21. September 1988

Publikationsdatum:
24. Juli 2018 (online)

 als PDF herunterladen  Lizenzen und Reprints
Preview

Summary

F(ab’)2 fragments of a murine monoclonal anti-platelet GPIIb/ IIIa antibody (7E3) are a potent platelet aggregation inhibitor, which in a canine coronary artery thrombosis model accelerate lysis with recombinant tissue-type plasminogen activator (rt-PA) and prevent reocclusion (7).

In the present study, we have investigated the potential value of platelet aggregation inhibition as adjunctive therapy to lysis of venous thrombi, by measuring the thrombolytic potency of 7E3- F(ab’)2 and rt-PA used alone or in combination, in dogs with a 125I-fibrin labeled femoral vein thrombus. The dose-response of thrombolysis with rt-PA infused over 4 hours was linear: doses of 0.075 mg/kg, 0.15 mg/kg and 0.3 mg/kg produced 37 ± 3, 57 ± 11 and 83 ± 4% lysis respectively, against a background value of 20 ± 2%. With F(ab’)2 fragments of 7E3 given as a bolus of 1.2 mg/ kg, which saturated 70% of the platelet GPIIb/IIIa receptors and prolonged the bleeding to more than 30 min, lysis was not significantly increased over background. Combination of 0.3 or 0.6 mg/kg of 7E3-F(ab’)2 with either 0.03 or 0.06 mg/kg of rt-PA did not produce more lysis than obtained with a comparable dose of rt-PA alone. No significant changes in plasma fibrinogen or α2- antiplasmin were observed with either agent alone or with the combination. It is concluded that extensive inhibition of platelet aggregation does not potentiate the thrombolytic effect of rt-PA in this venous thrombosis model.

Key words

Recombinant tissue-type plasminogen activator (rt-PA) - Platelet inhibition - Thrombolysis